Consistent with these findings, inhibiting PARP-1 activity in endothelial cells protects against endothelial dysfunction [26, 27] and PARP-1 inhibitors are under consideration as a treatment for pulmonary hypertension [28]. Here, PARP1 is linked to pulmonary hypertension.